Cemiplimab

Libtayo®

Cemiplimab is an IgG4 antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

June 2020

Monotherapy for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation therapy.

Intravenous infusion over 30 minutes: 350 mg every 3 weeks.

Complete blood count, blood chemistry panel (Na, K, chloride, calcium, phosphate, urea, creatinine, uric acid, bilirubin, AST, ALT, gamma-GT, alkaline phosphatase, LDH, pancreatic amylase, total protein, CRP, CK), glucose, cortisol, TSH, fT4, hs troponin T, troponin I, NT-pro BNP, S-100, pregnancy test as indicated, viral serology tests as needed (hepatitis B/C, HIV, CMV, EBV).

ECG, echocardiography (in cases of cardiovascular risk).

Prior to the start of therapy, systemic corticosteroids (>10 mg/day prednisone) or immunosuppressants should not be administered to avoid potential interference with cemiplimab therapy.

Before each dose: complete blood count, blood chemistry panel (Na, K, chloride, calcium, phosphate, urea, creatinine, uric acid, bilirubin, AST, ALT, gamma-GT, alkaline phosphatase, LDH, pancreatic amylase, total protein, CRP, CK), glucose, TSH, fT4, hs troponin T, troponin I, cortisol if necessary. S-100 every 3 months.

Treatment may be continued for up to 2 years, until the disease progresses or until unacceptable toxicity occurs.

See specialist literature, guidelines, and study results.